ArticleApplied biochemistry and biotechnology2026
OGT-mediated O-GlcNAcylation Protects Against Myocardial Ischemia-Reperfusion Injury via Targeting MG53.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Myocardial ischemia/reperfusion (I/R) injury poses a significant worldwide health burden. O-Linked β-N-acetylglucosamine transferase (OGT), an enzyme that catalyzes protein O-GlcNAcylation, is implicated in cellular stress responses, but its precise role and mechanism in cardioprotection are not fully elucidated. In this study, H9c2 cardiomyocytes were subjected to hypoxia/reoxygenation (H/R) to simulate I/R injury, and cardiomyocyte injury was evaluated by assessing cell viability, lactate dehydrogenase (LDH) release, apoptosis, and oxidative stress markers. In parallel, mice were pretreated with the OGT activator Thiamet-G or the OGT inhibitor OSMI-1 prior to left anterior descending artery ligation, followed by comprehensive evaluation of cardiac function, myocardial injury biomarkers, and histopathological changes. We found that OGT overexpression markedly attenuated H/R-induced cardiomyocyte injury, as evidenced by improved cell viability, reduced LDH release and apoptosis, and alleviated oxidative stress. Consistently, pharmacological activation of OGT improved cardiac function and reduced myocardial fibrosis following I/R injury in vivo, whereas OGT inhibition exerted the opposite effect. Mechanistically, co-immunoprecipitation, western blotting, and site-directed mutagenesis revealed that OGT enhances global protein O-GlcNAcylation and increases the stability of cardioprotective protein MG53 by catalyzing its O-GlcNAcylation at the Ser301 residue, and the protective effects of OGT were abolished in cardiomyocytes expressing the MG53 Ser301 mutant. Collectively, these findings demonstrate that MG53 is a key downstream substrate of OGT-mediated O-GlcNAcylation in myocardial I/R injury and provide mechanistic insight into how OGT confers cardioprotection, highlighting the OGT–MG53 axis as a potential therapeutic target for mitigating cardiac I/R injury.
Indexed as
Identifiers
41830977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.